NVAX Share Price

Open 1.14 Change Price %
High 1.15 1 Day -0.02 -1.75
Low 1.11 1 Week -0.02 -1.75
Close 1.12 1 Month 0.12 12.00
Volume 4543590 1 Year -0.37 -24.83
52 Week High 2.47
52 Week Low 0.73
NVAX Important Levels
Resistance 2 1.16
Resistance 1 1.14
Pivot 1.13
Support 1 1.10
Support 2 1.08
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
SCHS 0.04 33.33%
ZAZA 0.04 33.33%
GCFB 0.50 31.58%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LTRE 2.80 20.69%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
AMCF 0.01 -80.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PTSX 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Novavax, Inc. (NASDAQ: NVAX)

NVAX Technical Analysis 1.5
As on 18th Sep 2017 NVAX Share Price closed @ 1.12 and we RECOMMEND Sell for LONG-TERM with Stoploss of 1.21 & Buy for SHORT-TERM with Stoploss of 1.11 we also expect STOCK to react on Following IMPORTANT LEVELS.
NVAX Target for September
1st Target up-side 1.15
2nd Target up-side 1.23
3rd Target up-side 1.3
1st Target down-side 0.95
2nd Target down-side 0.87
3rd Target down-side 0.8
NVAX Other Details
Segment EQ
Market Capital 253984256.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.novavax.com
NVAX Address
NVAX
20 Firstfield Road
Gaithersburg, MD 20878
United States
Phone: 240-268-2000
NVAX Latest News
Interactive Technical Analysis Chart Novavax, Inc. ( NVAX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Novavax, Inc.
NVAX Business Profile
Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.